Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large
part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT …

Introduction Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase protein frequently
overexpressed in cancer and has been linked to an increase in the stem cell population of …

The effects of radiotherapy (RT) on tumor immunity in pancreatic ductal adenocarcinoma
(PDAC) are not well understood. To better understand if RT can prime antigen-specific T-cell …

Radiation therapy offers limited clinical benefits for patients with pancreatic cancer, partly as
a result of the predominantly immunosuppressive microenvironment characteristic of this …

Single-agent immunotherapy has achieved limited clinical benefit to date in patients with
pancreatic ductal adenocarcinoma (PDAC). This may be a result of the presence of a …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease known for its dense tumor
stroma. Focal adhesion kinase inhibitor (FAKi), a non-receptor type tyrosine kinase inhibitor …

Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells.
Focal adhesion kinase (FAK) is activated in PDA, and levels are inversely associated with …

Background Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease, with
minimal therapeutic options. Aberrant tyrosine kinase activity influences tumor growth and is …

Objective Immunotherapy for the treatment of pancreatic ductal adenocarcinoma (PDAC)
has shown limited efficacy. Poor CD8 T-cell infiltration, low neoantigen load and a highly …

Despite substantial advances in the treatment of solid cancers, resistance to therapy
remains a major obstacle to prolonged progression-free survival. Pancreatic ductal …